SOLIRIS (Eculizumab)

What is Soliris (Eculizumab)
Soliris is a humanised monoclonal antibody that is a first-in-class terminal complement inhibitor and the first therapy approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) , a rare, progressive, and sometimes life-threatening disease.


Drug Manufacturer / Marketeer :

M/s Alexion Pharmaceuticals, Inc.

Available as:

300MG single-use vials

Soliris is indicated for:

  • The treatment of patients of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
  • The treatment of patients with atypical haemolytic uremic syndrome (aHUS) to inhibit complement- mediated thrombotic microangiopathy.

For treatment related information, please consult your treating Physician.

How supplied:
Soliris is supplied as 300 mg single-use vials each containing 30 ml of 10 mg/ml sterile, preservative-free eculizumab solution.

Storage and handling:
Soliris vials must be stored in the original carton until time of use under refrigerated conditions at 2-8°C and protected from light.

How do we source the Drug?
SMIQ Pharma-India will assist in sourcing the drug through its efficient network,  across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.

Company that Manufactures/ Markets:
M/s Alexion Pharmaceuticals, Inc.

Assistance Cell in India:
For ONCOLOGY DRUG: SOLIRIS (Eculizumab) 300MG price.

Contact us @ +91 7678048225 or by email